TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Yale researchers are joining three lines of preclinical work on misfolded alpha-synuclein, a protein linked to Parkinson’s disease. The teams will study how nerve cells take it up, how lymphatic vessels clear it, and whether a mouse model based on patients’ cerebrospinal fluid can better represent disease progression. The work is investigative; it has not shown that Parkinson’s can be prevented in people.
Yale School of Medicine researchers are working across three teams to investigate how misfolded alpha-synuclein moves between brain cells, is cleared from the brain, and may contribute to Parkinson’s disease. The project, funded by Aligning Science Across Parkinson’s, is intended to clarify possible disease mechanisms and treatment targets; it has not established a way to prevent Parkinson’s in people.
One team, led by neurologist Stephen Strittmatter, is examining which proteins help neurons take up misfolded alpha-synuclein from the spaces between cells. The researchers screened thousands of proteins and identified about 15 that could bind labeled synuclein. They focused on mGluR4 and NPDC1 because those two were selectively expressed in dopamine-containing neurons, which are especially affected in Parkinson’s.
In preclinical models, genetically removing either or both proteins prevented the loss of dopamine-related neurons usually seen in those models, according to the report. That result does not show that a drug acting on either protein would have the same effect in people. Strittmatter said the team wants to test drugs that target mGluR4 at different points in the disease process, rather than relying only on deleting the gene.
A second team, led by Eric Song, will study whether lymphatic vessels can clear extracellular alpha-synuclein before it is taken up by nearby neurons. A third team, led by Le Zhang, is developing a mouse model using cerebrospinal fluid from people with Parkinson’s. In the team’s reported experiments, infusions of patient fluid led over time to Parkinson’s-like symptoms and alpha-synuclein aggregation in mouse brains. The groups plan to connect these approaches to investigate how the protein’s movement and clearance relate to disease.
Testing Routes to Limit Protein Spread
The project addresses a potential point of intervention: alpha-synuclein outside neurons, before it is taken up by another cell. If researchers can establish how the protein is cleared or what makes neurons absorb it, those processes could point to targets for future treatments. The work also brings together studies of uptake, waste clearance and disease modelling, rather than treating each as a separate question.
For people affected by Parkinson’s, the immediate significance is scientific, not clinical. The findings described so far come from preclinical research, and no prevention method or treatment benefit in patients is reported. Researchers still need to establish whether changing these processes can alter disease in relevant models and whether any such effects can translate to people.
Products Worth Considering
Therabody Theragun Mini 3rd Generation Massage Gun, Black
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
Oral-B iO Series 9 Limited Rechargeable Electric Toothbrush with 7 Cleaning Modes
As an affiliate, we earn on qualifying purchases.
How the Teams Approach Alpha-Synuclein
Alpha-synuclein is present in healthy brains and has a role in communication between nerve cells. In some circumstances, misfolded forms can collect into Lewy bodies, protein clusters associated with Parkinson’s disease and some forms of dementia. Researchers have also found that misfolded alpha-synuclein can move between cells through fluid spaces in the brain, raising questions about what happens to it between leaving one neuron and entering another.
Existing Parkinson’s preclinical models often introduce alpha-synuclein fibrils into mouse brains or alter mouse genes so the animals produce too much of the protein. The Yale teams say those approaches do not closely reproduce the extracellular protein that Strittmatter’s group wants to study. Zhang’s patient-fluid model may provide another way to examine disease-related processes, though the proposed explanation for how the fluid produces effects in mice remains a hypothesis.
“What is the balance between moving it out of the brain versus being taken up into another neuron and spreading disease?”
— Stephen Strittmatter, Yale School of Medicine
Key Questions Before Human Tests
The report does not say whether blocking mGluR4 or NPDC1 with a drug will protect neurons, what treatment timing might matter, or whether the preclinical effects can be reproduced in people. It also provides no clinical trial results or evidence that changing lymphatic clearance prevents Parkinson’s disease.
The mechanism behind the patient-fluid model remains unsettled. Zhang’s suggestion that alpha-synuclein and human autoantibodies could form an immune complex is described as a current hypothesis. The report does not specify the number of patient samples, the full experimental methods, or when the combined research will produce results.
Experiments to Test Clearance and Uptake
The teams’ next work is to investigate how alpha-synuclein is handled outside neurons: which proteins enable its uptake, whether lymphatic vessels can clear it, and how those processes relate to the patient-fluid mouse model. Strittmatter has said drug-based tests targeting mGluR4 at different time points would help assess its potential as a therapeutic target.
The researchers have not announced a clinical trial timeline or a date for results. Any claims about preventing Parkinson’s in people will depend on further experiments and, if findings support it, later testing in humans.
Key Questions
Has this research shown how to prevent Parkinson’s disease?
No. The reported work is preclinical and investigates possible mechanisms and targets. It does not establish a prevention method for people.
What is alpha-synuclein?
It is a protein found in healthy brains that plays a role in communication between nerve cells. Misfolded alpha-synuclein can form clusters associated with Parkinson’s disease and some forms of dementia.
What did the Yale teams find about mGluR4 and NPDC1?
In preclinical models, genetically removing either or both proteins prevented the loss of dopamine-related neurons usually seen in those models. The report does not show that drug treatments targeting these proteins work in people.
How might lymphatic vessels relate to Parkinson’s research?
One team will study whether lymphatic vessels can clear alpha-synuclein from the spaces outside brain cells before nearby neurons take it up. Whether this approach can affect Parkinson’s disease remains unknown.
When could the findings lead to a treatment?
No clinical timeline is given. The researchers first need to test their ideas in preclinical work; the report does not announce human trials or expected treatment dates.
Source: rss
